Erenumab Reduces Flushing and Erythema in Rosacea
A calcitonin gene-related peptide inhibitor that is FDA-approved for migraine prevention showed early promise against treatment-resistant redness and flushing of rosacea.
Stay updated with breaking news from Johns Barbieri. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A calcitonin gene-related peptide inhibitor that is FDA-approved for migraine prevention showed early promise against treatment-resistant redness and flushing of rosacea.
The new guidelines updated the AAD's 2016 guidelines and included 18 recommendations and five good practice statements.
In new guidelines by the AAD, 18 new evidence-based recommendations and 5 practice statements were described for patients 9 years of age and older with acne.
Acne is the most common skin condition in the United States, affecting nearly 50 million Americans each year, with symptoms usually beginning in puberty.
Only a minority of patients with psoriatic disease know about their increased risks.